Vanda Pharmaceuticals Inc. (VNDA)
$4.30-5.29%Close
SELLCRISIS · day 8
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $259M
- Beta
- 0.69
- P/E (TTM)
- -0.93
- Short % float
- 14.55%
- Days to cover
- 6.5
- SI change
- -7.8%
- 1W
- -4.87%
- 1M
- -16.50%
- vs SPY 1W
- -4.73%
- vs SPY 1M
- -19.01%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 9
- VALUE
- 5
- GROWTH
- 43
- GARP
- 6
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-51.0%
REV YoY-
ROE-85.0%
EPS YoY-
ROA-66.6%
GROSS93
OP-86
NET-127
[VALUATION]
P/E TTM-0.93
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B1.18
P/FCF-
EV/EBITDA-1.37
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E10.37
ALTMAN Z-
CURR RATIO1.61
ND/EBITDA-
BETA0.69
Company news
FAQ
- What is LOPJLB’s current signal on VNDA?
- LOPJLB’s latest quantitative signal on Vanda Pharmaceuticals Inc. (VNDA) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is VNDA in?
- Vanda Pharmaceuticals Inc. (VNDA) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Vanda Pharmaceuticals Inc. (VNDA) do?
- Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions that address critical unmet medical needs. The company currently offers two approved treatments: HETLIOZ, prescribed for non-24-hour sleep-wake disorders, and Fanapt oral tablets, used in the management of schizophrenia. Vanda maintains an active and diverse development pi…